Given our observation that CCR8 also marks Tconv cells whose suppressive function is induced upon experimental Treg cell ablation in vivo, it is reasonable to postulate that depletion of CCR8-expressing cells is a superior approach to Treg cell depletion using other Treg cell-expressed markers for induction of anti-tumor immunity, since CCR8-depleting therapies would target both Treg cells and suppressive Tconv cells for destruction. This evidence concerns the gene CCR8 and neoplasm.